Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Andrew D. Fesnak"'
Autor:
Andrew D. Fesnak, Don L. Siegel
Publikováno v:
Rossi's Principles of Transfusion Medicine. :633-641
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::97c6a607a05cd1968f3e37f728b31630
https://doi.org/10.1002/9781119719809.ch55
https://doi.org/10.1002/9781119719809.ch55
Autor:
Barbara Savoldo, Gerhard Bauer, Brian G. Till, Peter Marks, Helen E. Heslop, Andrew D. Fesnak, Steven A. Feldman, Magdi Elsallab, Mohamed Abou-el-Enein
Supplementary Data from Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40c9f72194e95c7d56059a0c2e79e392
https://doi.org/10.1158/2643-3230.22543887
https://doi.org/10.1158/2643-3230.22543887
Autor:
Barbara Savoldo, Gerhard Bauer, Brian G. Till, Peter Marks, Helen E. Heslop, Andrew D. Fesnak, Steven A. Feldman, Magdi Elsallab, Mohamed Abou-el-Enein
As of April 2021, there are five commercially available chimeric antigen receptor (CAR) T cell therapies for hematologic malignancies. With the current transition of CAR T cell manufacturing from academia to industry, there is a shift toward Good Man
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10e38dcc00964eaa1f4ed05f6ec5f92e
https://doi.org/10.1158/2643-3230.c.6550449
https://doi.org/10.1158/2643-3230.c.6550449
Publikováno v:
Successful Drug Discovery
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a8bcbfcdd3d500a1eb59bfe5b81669a4
https://doi.org/10.1002/9783527826872.ch5
https://doi.org/10.1002/9783527826872.ch5
Autor:
Andrew D. Fesnak, Anne Lamontagne
Publikováno v:
Cell and Gene Therapy Insights. 6:157-1363
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5e7c640bd4976472273f1c6679978184
https://doi.org/10.18609/cgti.2020.149
https://doi.org/10.18609/cgti.2020.149
Autor:
Magdi Elsallab, Gerhard Bauer, Steven A. Feldman, Helen E. Heslop, Brian G. Till, Andrew D. Fesnak, Mohamed Abou-El-Enein, Barbara Savoldo, Peter W. Marks
Publikováno v:
Blood Cancer Discov
As of April 2021, there are five commercially available chimeric antigen receptor (CAR) T cell therapies for hematologic malignancies. With the current transition of CAR T cell manufacturing from academia to industry, there is a shift toward Good Man
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3796b75af92ccdec40f01cd15138e557
https://pubmed.ncbi.nlm.nih.gov/34568831
https://pubmed.ncbi.nlm.nih.gov/34568831
Autor:
Pamela A Shaw, Don L. Siegel, Andrew D. Fesnak, Christina Fasano, Kelly D. Getz, Richard Aplenc, Jennifer Brogdon, Amanda M. DiNofia, Allison Barz Leahy, Yimei Li, Megan M. Davis, Diane Baniewicz, Hongyan Liu, Lisa Wray, Carl H. June, David T. Teachey, Elizabeth O. Hexner, Stephan A. Grupp, Edward Pequignot, Bruce L. Levine, Colleen Callahan, Simon F. Lacey, Shannon L. Maude, Gerald Wertheim, Anne Chew, Chelsie Bartoszek, Regina M. Myers, Susan R. Rheingold, David M. Barrett
Publikováno v:
J Clin Oncol
PURPOSE CD19-targeted chimeric antigen receptor (CAR)–modified T cells demonstrate unprecedented responses in B-cell acute lymphoblastic leukemia (B-ALL); however, relapse remains a substantial challenge. Short CAR T-cell persistence contributes to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::103c6ddb241c52b015b2819f4f73f18a
https://pubmed.ncbi.nlm.nih.gov/34156874
https://pubmed.ncbi.nlm.nih.gov/34156874
Autor:
Chip White, Reid Bishop, Andrew D. Fesnak, Junxuan Li, Ben Wang, Linda Ho, Kan Wang, Amritava Das, Aaron D. Levine, Yi Liu, Bruce L. Levine
Publikováno v:
Cytotherapy. 21:1081-1093
Background aims Autologous cell therapy (AuCT) is an emerging therapeutic treatment that is undergoing transformation from laboratory- to industry-scale manufacturing with recent regulatory approvals. Various challenges facing the complex AuCT manufa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5190ac2d3642626f7ba34ea735e3679a
https://doi.org/10.1016/j.jcyt.2019.07.002
https://doi.org/10.1016/j.jcyt.2019.07.002
Autor:
Andrew D. Fesnak
Publikováno v:
Regen Eng Transl Med
Autologous Chimeric Antigen Receptor (CAR) T cell manufacturing involves the modification and expansion of T cells obtained by apheresis collection from a patient. The mechanism of apheresis collection and the specific clinical features seen in these
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e5dddf66acc7b13d8f4732c85bfb131
https://doi.org/10.1007/s40883-019-00124-3
https://doi.org/10.1007/s40883-019-00124-3
Autor:
Andrew D. Fesnak, Ryan J. Golden
Publikováno v:
Transfus Apher Sci
Both natural killer (NK) cells and T cells demonstrate potent antitumor responses in many settings. NK cells, unlike T cells, are not the primary mediators of graft-versus-host disease (GVHD). Redirection of T cells with chimeric antigen receptors (C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a4f22a8f98c9b276de3a09a4c7bf479
https://pubmed.ncbi.nlm.nih.gov/33468407
https://pubmed.ncbi.nlm.nih.gov/33468407